Low Dietary Sodium and Exogenous Angiotensin II Infusion Decrease Plasma Adiponectin Concentrations in Healthy Men

Lely, A. Titia; Krikken, Jan A.; Bakker, Stephan J. L.; Boomsma, Frans; Dullaart, Robin; Wolffenbuttel, Bruce H. R.; Navis, Gerjan

doi:10.1210/jc.2006-2092

Cited by 51 publications

(58 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ACEI and ARB have been reported to increase the plasma adiponectin concentration in patients with hypertension, [20][21][22] and β-blockers might decrease plasma adiponectin in patients with coronary artery disease. 23 Therefore, there were no consistent results of anti-CHF drugs on the effects of plasma adiponectin, one of the important prognostic predictors.…”

Section: Discussionmentioning

confidence: 95%

Effect of Carvedilol on Plasma Adiponectin Concentration in Patients With Chronic Heart Failure

Yamaji

Tsutamoto

Tanaka

et al. 2009

Circ J

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 95%

Effect of Carvedilol on Plasma Adiponectin Concentration in Patients With Chronic Heart Failure

Yamaji

Tsutamoto

Tanaka

et al. 2009

Circ J

View full text Add to dashboard Cite

“…Conflicting results were reported in human studies. While no changes in adiponectin levels were observed with perindopril treatment [30], increased levels were found with enalapril [27], ramipril [18] or temocapril [15]. As ACE inhibitors reduce angiotensin II production and prevent bradykinin degradation, both mechanisms may be involved in the changes in adiponectin levels.…”

Section: Discussionmentioning

confidence: 97%

“…The protective effects of adiponectin may be explained by cross talk between adipose tissue hormones and RAAS. In fact, previous studies reported that angiotensin II infusion or ACEi administration evoked significant increases in adiponectin levels in healthy individuals [27]. Moreover, diet-induced obese mice treated with enalapril showed reduction in energy intake and body mass associated with higher serum adiponectin and insulin sensitivity improvement [28].…”

Section: Discussionmentioning

confidence: 98%

Effects of Angiotensin‐Converting Enzyme Inhibition on Leptin and Adiponectin Levels in Essential Hypertension

Fontana

Faria

Oliveira-Paula

et al. 2014

Basic Clin Pharma Tox

View full text Add to dashboard Cite

Activation of the renin-angiotensin-aldosterone system (RAAS) and abnormal adipokine levels are biological alterations that affect blood pressure regulation and interact to link hypertension, obesity and metabolic diseases. While imbalanced levels of hormones produced by adipocytes including hypo-adiponectinaemia and hyperleptinaemia were reported in hypertension, little is known about how antihypertensive therapy affects these alterations. This study aimed to evaluate the effects of enalapril on plasma adiponectin and leptin levels in hypertensive individuals. Thirty-seven untreated hypertensive patients were prospectively treated with enalapril for 8 weeks. Blood samples were collected at baseline and after the treatment with enalapril. Plasma adiponectin and leptin levels were measured by enzyme-linked immunoassay. We found significant increases in adiponectin levels after enalapril treatment (5.4 AE 3.7 versus 6.0 AE 4.5 lg/mL, meanAES.D., p = 0.04). Conversely, leptin levels were unchanged (18.0 AE 14.7 versus 18.4 AE 14.8 ng/mL, mean AE S.D., p = 0.31). Multiple linear regression revealed that baseline leptin is a significant predictor of systolic blood pressure reduction (b=0.269, p = 0.01) in hypertensive individuals treated with enalapril. While enalapril increases adiponectin levels in hypertensive individuals, baseline leptin levels predict blood pressure reduction in response to this therapy. These findings support the idea of an important relationship between RAAS and adipose tissue in hypertension and suggest that enalapril improves the adipokine profile, possibly allowing beneficial effects to overweight or obese hypertensive individuals.Hypertension, obesity and metabolic abnormalities share common physiopathological mechanisms including activation of the renin-angiotensin-aldosterone system (RAAS) and alterations in adipokine levels [1]. Adiponectin and leptin are hormones produced by adipocytes [2] and imbalanced levels of these hormones have been shown in hypertensive patients compared with normotensive controls [3]. An inverse relationship between adiponectin and blood pressure (BP) levels was reported, and hypo-adiponectinaemia has been suggested as a risk factor for hypertension [3]. The cardiovascular protective effects of adiponectin are mediated by anti-inflammatory, insulin-sensitizing and antiatherogenic mechanisms [4][5][6]. On the other hand, hyperleptinaemia promotes cardiovascular remodelling [7,8] mainly by increasing sympathetic nervous system activity [9]. Indeed, increased leptin levels may predict development of hypertension, independent of BMI and insulin resistance [10].Increasing evidence suggests that RAAS and adipose tissue are interplayers in BP regulation [11][12][13]. It has been suggested that angiotensin-converting enzyme inhibitors (ACEi) may offer advantages as monotherapy in the treatment of obese hypertensive individuals, particularly in the prevention of metabolic disorders [14]. Moreover, some studies demonstrated that drug interfering with RAAS can i...

show abstract

“…Prior studies have demonstrated that adipocytes secrete other factors that stimulate aldosterone release from the adrenal cortex. In vitro studies have specifically identified the involvement of the Wnt-signaling pathway and mitogen-activated protein kinases in adipocyte-stimulated aldosterone release [18][19][20][21] . Several studies have demonstrated a clear inverse relationship between the level of plasma aldosterone and the level of plasma adiponectin.…”

Section: Aldosterone and Adiponectinmentioning

confidence: 99%

Interaction between Adiponectin and Aldosterone

Flynn

Bakris²

2011

Cardiorenal Med

View full text Add to dashboard Cite

More than two thirds of the US population are considered overweight or obese. Adipocytes are now appreciated as important endocrine organs, secreting various factors with hormonal effects. Several different adipokines have been identified, including adiponectin, which is associated with improved insulin sensitivity, a better lipoprotein profile, and lower rates of vascular inflammation and cardiovascular disease. Several studies have identified the renin-angiotensinaldosterone system as important in the regulation of adiponectin. These studies lay the fundamental groundwork for developing targeted therapies with potential to reduce the burden of obesity-associated diseases, such as the cardiorenal metabolic syndrome.

show abstract

Low Dietary Sodium and Exogenous Angiotensin II Infusion Decrease Plasma Adiponectin Concentrations in Healthy Men

Abstract: Physiological and pharmacological modulation of RAAS affects plasma adiponectin with lower concentrations during the high angiotensin II conditions. The therapeutic potential of RAAS blockade as a tool to correct hypoadiponectinemia should be explored further.

Cited by 51 publications

References 37 publications

Effect of Carvedilol on Plasma Adiponectin Concentration in Patients With Chronic Heart Failure

Effect of Carvedilol on Plasma Adiponectin Concentration in Patients With Chronic Heart Failure

Effects of Angiotensin‐Converting Enzyme Inhibition on Leptin and Adiponectin Levels in Essential Hypertension

Interaction between Adiponectin and Aldosterone

Contact Info

Product

Resources

About